Country Bans Puberty Blockers for Transgender Minors
The United Kingdom on Wednesday indefinitely banned new prescriptions of puberty blockers to treat minors for gender dysphoria. The announcement comes a week after the U.S. Supreme Court heard oral arguments in a case involving state bans on puberty-suppressing medication and other forms of transition-related care for minors. . .
The indefinite ban on the medication in Britain comes several months after an independent study commissioned by England’s National Health Service concluded that the medical evidence around transition-related care for minors is “remarkably weak” and that more research is needed.
“Children’s healthcare must always be evidence-led,” British Health and Social Care Secretary Wes Streeting said in a press release. “The independent expert Commission on Human Medicines found that the current prescribing and care pathway for gender dysphoria and incongruence presents an unacceptable safety risk for children and young people.”
Dr. Hilary Cass, the author of the independent study, known as the “Cass report,” said she supported the ban, according to the same release.
“Puberty blockers are powerful drugs with unproven benefits and significant risks, and that is why I recommended that they should only be prescribed following a multi-disciplinary assessment and within a research protocol,” she said. (Read more from “Country Bans Puberty Blockers for Transgender Minors” HERE)
